Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII

16 Nov 2016

Abstract excerpt

Replacement therapy with factor VIII (FVIII) is used in patients with hemophilia A for treatment of bleeding episodes or for prophylaxis. A common and serious problem with this therapy is the patient's immune response to FVIII, because of a lack of tolerance, leading to the formation of inhibitory antibodies. Development of tolerogenic therapies, other than standard immune tolerance induction (ITI), is an unmet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia Treatment and Research
Share to Immunodeficiency and Autoimmune Disorders
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28064157
DOI: 10.1182/blood-2016-07-727834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIIIPMID 28064157Read ↗

CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII.Semantic proximity Read ↗

T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.Semantic proximity Read ↗

Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transferSemantic proximity Read ↗

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?Semantic proximity Read ↗

Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipientsSemantic proximity Read ↗

Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophiliaSemantic proximity Read ↗

Gene editing of <i>CD3 epsilon</i> gene to redirect regulatory T cells for adoptive T cell transferSemantic proximity Read ↗

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.Semantic proximity Read ↗

Anti-CD19 CAR-T cell therapy for acquired hemophilia ASemantic proximity Read ↗

HLA-A2 CAR/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory functionSemantic proximity Read ↗

HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease.Semantic proximity Read ↗

Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.